ArticleClinical epigenetics2025
Decoding epigenetic and transcriptional landscapes: DNA methylome-transcriptome integration reveals novel drivers in 4NQO-Induced esophageal squamous cell carcinoma mouse model.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpigenetic alterations, particularly DNA methylation, and dysregulation of the tumor immune microenvironment (TIME) are increasingly recognized as critical factors in esophageal squamous cell carcinoma (ESCC) pathogenesis. Understanding the dynamic interplay between DNA methylation changes and TIME evolution during ESCC progression remains essential. We established a 4-nitroquinoline 1-oxide (4NQO)-induced ESCC mouse model, capturing distinct pathological stages: normal esophageal epithelium (Normal), esophageal simple hyperplasia (ESSH), intraepithelial neoplasia (IEN), and ESCC. Genome-wide DNA methylation profiling was performed using the Infinium Mouse Methylation BeadChip (285 K), coupled with transcriptome analysis via bulk RNA sequencing (RNA-seq). Immunohistochemistry (IHC) for Cd45 (leukocyte common antigen) validated immune cell infiltration.
resultsDNA methylation profiling revealed progressive genome-wide hypomethylation during ESCC development, with hypomethylated probes significantly enriched in immune response pathways. Notably, ESSH exhibited a methylation profile similar to IEN and ESCC. RNA-seq identified escalating numbers of differentially expressed genes (DEGs). Immune deconvolution analysis and IHC of Cd45 demonstrated dynamic changes in TIME composition from ESSH onwards. Furthermore, dynamic expression clustering identified an innate immune response-related gene cluster highly expressed in ESSH. Integrative analysis yielded 495 methylated regulatory genes, significantly enriched in leukocyte cell-cell adhesion and T cell activation pathways (e.g., Ptprc/Cd45, Il12rb1, Tox), with peak activity in ESSH.
conclusionsThese findings highlight ESSH as a critical window where epigenetically driven immune changes facilitate ESCC progression. Targeting these early epigenetic-immune interactions may offer a novel strategy for ESCC early detection and combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.